Browsing Tag
PTC Therapeutics
8 posts
Top U.S. gainers: Regencell, Disney, Rockwell, and Tempus AI spark broad market rally
Explore which U.S. stocks surged on May 7, 2025, and why investors rotated into biotech, AI, and healthcare amid Fed pauses and macro uncertainty.
PTC Therapeutics, TG Therapeutics, and Zimmer Biomet among top U.S. stock losers
See which U.S. stocks fell the most on May 5, 2025, and why—an in-depth look at the market’s biggest losers amid trade tensions and sector-specific headwinds.
FDA approves Genentech’s Evrysdi tablet as first SMA treatment in tablet form
In a significant development for the treatment of spinal muscular atrophy (SMA), the U.S. Food and Drug Administration…
Breakthrough data from Vatiquinone trials propels PTC Therapeutics stock to 52-week high
PTC Therapeutics Inc. (NASDAQ: PTCT) is experiencing significant momentum within the biotechnology sector following a surge in its…
FDA accepts PTC Therapeutics’ NDA for Sepiapterin, aiming for breakthrough in PKU treatment
PTC Therapeutics, Inc. has announced a significant step forward in its mission to combat phenylketonuria (PKU) by receiving…
PTC Therapeutics collaborates with Royalty Pharma in $1.5bn Evrysdi royalty agreement
PTC Therapeutics, Inc. (NASDAQ: PTCT) has forged an agreement with Royalty Pharma plc., monetizing up to a staggering…
PTC Therapeutics secures Russian approval for Translarna to treat Duchenne muscular dystrophy
PTC Therapeutics, a leading US-based biotechnology company, has received marketing approval in Russia for its innovative drug, Translarna…
PTC Therapeutics completes $200m acquisition of Agilis Biotherapeutics to expand gene therapy portfolio
In a major strategic move, US biopharmaceutical company PTC Therapeutics has finalized its acquisition of Agilis Biotherapeutics, a…